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Persistent facial pains, especially temporoman-
dibular disorders (TMD), are common condi-
tions. As dentists are responsible for the treat-
ment of most of these disorders, up-to date 
knowledge on the latest advances in the field 
is essential for successful diagnosis and man-
agement.  The review covers TMD, and differ-
ent neuropathic or putative neuropathic facial 
pains such as persistent idiopathic facial pain 
and atypical odontalgia, trigeminal neuralgia 
and painful posttraumatic trigeminal neuropa-
thy. The article presents an overview of TMD 
pain as a biopsychosocial condition, its preva-
lence, clinical features, consequences, central 
and peripheral mechanisms, diagnostic criteria 
(DC/TMD), and principles of management. For 
each of the neuropathic facial pain entities, the 
definitions, prevalence, clinical features, and 
diagnostics are described. The current under-
standing of the pathophysiology of these enti-
ties is presented, and a description of the evi-
dence based treatment methods is provided. 
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Persistent facial pains, especially temporomandibular disorders (TMD), are common conditions; their prev-alence is in the range of 8-15%. As patients often pre-sent complaints of facial pain to their dentist, it is im-
portant that dentists are familiar with these conditions. Many 
advances have been made during recent decades in the under-
standing of chronic facial pain, such as increased knowledge of 
the peripheral and central neural processes involved in differ-
ent facial pain entities, recognition of the multidimensional na-
ture of pain, and improvements in evidence-based treatments, 
both physical and behavioural, for different conditions. The 
present article aims to provide up-to-date information on dif-
ferent chronic facial pain entities to enhance their recognition 
and proper treatment or referral.
Temporomandibular disorders
Temporomandibular disorders (TMD) are recognized as a 
group of musculoskeletal and neuromuscular conditions that 
involve the temporomandibular joints (TMJs), the masticatory 
muscles, and associated tissues (1). The most common signs 
and symptoms of TMD are orofacial pain and impaired jaw 
function. TMD patients often suffer from other painful disor-
ders, and other comorbidities, such as sleep 
disorders. The chronic forms of TMD pain 
may lead to absence from or impairment of 
work or social interactions, resulting in an 
overall reduction in the quality of life. 
TMD is common in the adult population 
and seem to affect women more than men 
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(2), and the prevalence is reported to be between 5-12 % (3). 
The prevalence is lowest in children, and symptoms and clinical 
findings increase through adolescence, peak in adulthood and 
seem to decrease in the elderly. Muscle disorders, disc displace-
ments, and other joint disorders are frequent findings in the pa-
tients. As in other joints there may be pathological changes of 
the TMJs both because of localized degenerative joint diseases 
or systemic diseases. However, most disorders are primary and 
localized, and can be divided into non-infectious inflamma-
tory disorders, and disc displacements and degenerative joint 
disorders. The conditions may be associated with a feeling of 
tenderness, stabbing or radiant pain from the joints during 
rest and shooting pain during jaw function. In addition the jaw 
movements may be restricted, irregular or asymmetric and as-
sociated with TMJ clicking or crepitation, and secondarily the 
chewing pattern may be changed and the bite force reduced 
(4). Disorders of the masticatory muscles often start gradually 
as episodes of fatigue, tension and stiffness, which may evolve 
into more persistent dull and pressing pain localized to the 
cheeks, jaws, temples or even headache. 
Central and peripheral mechanisms
The pathophysiology and aetiology of TMD are not yet well 
understood. Peripheral and central sensitization seems to con-
tribute synergistically to this condition, which may explain why 
many of these patients need multidisciplinary and multimodal 
approaches to diagnostics and therapy (5).
The relation between peripheral pathology and pain mani-
festations is often weak in chronic orofacial pain. For exam-
ple, clinical signs and symptoms of TMD do not discriminate 
between treatment responders and non-responders (6). TMD 
patients seem to be more sensitive than TMD-free controls 
to experimental pain, both in the orofacial areas as well as in 
other parts of the body (7,8). While central mechanisms have 
been implicated in this increased sensitivity, there is also a role 
of peripheral sensitization that contributes to changes in noci-
ceptive and sensory input. Experimental injections of algesic 
substances like bradykinin, serotonin and glutamate into jaw 
muscle tissue result in muscle pain similar to that observed in 
patients with chronic myalgia of the masticatory muscles (8,9). 
There is also convincing evidence that peripheral changes in 
the levels of certain mediators in the TMJ and masticatory mus-
cle are related to pain. In particular, mediators like cytokines 
and serotonin have been investigated in both the TMJ and mus-
cle tissues (10). 
Central sensitization refers to neurofunctional changes of 
the somatosensory system in the spinal cord, brain stem and 
the brain pain matrix (11). There is substantial evidence that 
central pain mechanisms are disturbed in chronic orofacial 
pain. For example, reduced cognitive ability predicts treatment 
outcome (6). Furthermore, chronic orofacial pain patients 
show increased spatial distribution of TMD pain, increased 
temporal summation in remote body areas (12) and impaired 
central modulation of pain (13,14). Aberrant activation pat-
terns have been demonstrated in response to painful stimuli in 
chronic pain states such as fibromyalgia (15), a chronic pain 
condition often associated with TMD.
The multidimensionality of pain perception is supported 
by activation of brain areas not only associated with the per-
ception of sensory features (e.g. somatosensory cortices) but 
even more so regions associated with emotional and cognitive 
aspects of pain (16). These regions are known to play critical 
roles in various aspects of pain experiences. In addition, brain 
areas involved in the regulation of the autonomic nervous sys-
tem and endogenous pain modulation are affected. In an fMRI 
study, during periods of ongoing low back pain only brain re-
gions of importance for emotional and cognitive aspects of pain 
were activated (17). These findings indicate that the perception 
of chronic, ongoing pain requires only limited involvement of 
the somatosensory areas. Central sensitization is still difficult 
to clinically assess and quantify but may impact all levels of the 
biopsychosocial model of chronic pain: biological changes, psy-
chological aspects and social aspects.
Diagnosis of TMD in general and specialist practice
The recently published Diagnostic Criteria for Temporoman-
dibular Disorders (DC/TMD; 18) provides a simple and highly 
accurate methodology to diagnose TMD. DC/TMD comprises 
two axes; Axis I that provides a diagnosis of the clinical con-
dition (orofacial pain of myogenous or arthrogenous origin, 
headache attributed to TMD as well as disc displacement and 
degenerative joint disease) while Axis II provides a biopsycho-
social estimate of the degree of psychosocial distress. The DC/
TMD is currently available in English and Swedish but transla-
tions into at least 25 more languages are ongoing. For Finnish, 
Dutch and German the translation process is very near comple-
tion and these translations may very well be available at this 
time. Please see www.rdc-tmdinternational.org for details.
DC/TMD diagnostics is divided into three levels: screen-
ing, a short version for general dentistry and a comprehensive 
version to be used in specialist clinics. The aim of the screen-
ing is to identify patients with potential TMD symptoms. This 
is possible by asking each patient two questions with a “Yes” 
or “No” alternative: i) Do you have pain in the temples, face, 
temporomandibular joints or jaws once a week or more often? 
and ii) Do you have pain when you open your mouth or chew 
once a week or more often? If the patient answers “Yes” on one 
or two questions, it is highly likely that the patient has a DC/
TMD diagnosis (sensitivity: 0.98, specificity 0.83 for the two 
first questions; 19). The majority of patients identified with this 
instrument request treatment for their problems, making this 
instrument clinically relevant and useful (20). 
The clinical DC/TMD examination may lead to one or more 
Axis I diagnoses and will provide information about psychoso-
cial factors of importance in Axis II. Axis I diagnostics uses in-
formation from a questionnaire as well as findings in the struc-
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tured clinical examination. The clinical examination is strictly 
specified, including commands to the patient and palpation 
sites. Axis II evaluation of psychosocial factors uses validated 
questionnaires with established cut-offs. The questionnaires 
recommended in DC/TMD cover most aspects of pain and its 
consequences as well as risk factors for chronic pain (18). The 
purpose is to assess to what degree psychosocial factors con-
tribute, and to use this information to guide treatment planning 
and to evaluate prognosis. In general practice, these instru-
ments can also guide whether to refer the patient or to begin 
treatment. 
The DC/TMD does not cover all chronic orofacial pain and 
jaw dysfunction conditions. The Expanded DC/TMD Taxonomy 
(21) attempts to broaden the list of conditions, including gen-
eralized pain conditions involving the orofacial region. Condi-
tions not covered by the current DC/TMD, like neuropathic or 
cervicogenic types of pain, arthritis, fibromyalgia etc., so far 
need to be assessed and diagnosed according to other diagnos-
tic methodologies and criteria.
Principles of management
As TMD is considered to be a complex, multisystem disorder 
with multiple causes and comorbidities, and a strong genetic 
susceptibility (22), management rather than cure is the realis-
tic approach to the treatment of this disorder. The general goal 
of management is to alleviate pain, minimize the consequences 
of the chronic pain on the patient and restore normal jaw func-
tions. Unless there are specific and justifiable indications to the 
contrary, treatment of TMD patients should be based on the use 
of conservative, reversible therapeutic modalities as studies of 
the natural history of many TMDs suggest that they tend to im-
prove or resolve over time (1). The fact that widely differing 
treatment modalities produce comparable treatment effects, 
suggesting that the positive outcomes of treatment are prob-
ably at least partially due to non-specific factors, also speaks for 
the use of simple methods. When planning treatment several 
factors, such as physical symptoms and findings, psychosocial 
status of the patient, the impact of pain, pain chronicity, the 
presence of comorbid pain conditions, and the presence of co-
morbid disorders need to be taken into account. A special focus 
should be on person-specific or Axis II factors, as these are very 
important in terms of affecting disease course and response to 
treatment (23). According to a recent study, most primary care 
TMD patients report mild symptoms and are psychosocially 
well functioning, while only about 10% of patients report se-
vere symptoms and pain-related psychosocial distress (24). 
As there is evidence showing that functional TMD patients 
can be helped by simple means such as counselling, self-care 
and jaw exercises (25), most TMD patients can be easily treated 
by primary care dentists. Thus TMD pain may be reduced and 
jaw mobility, chewing function and bite force restored with 
conservative therapy in terms of reassurance and counselling, 
therapeutic home exercises and relaxation of the jaw, occlusal 
appliances, thermal physical therapy and temporary use of an-
algesics, non-steroidal anti-inflammatory drugs (NSAIDs), and 
intra-articular injections with glucocorticoid (26). In severe 
and complicated TMD, a team approach, usually consisting of a 
dentist, psychologist, and a physiotherapist, is needed. The ef-
ficacy of different TMD treatment methods, as well as the mul-
tidisciplinary/multimodal management of patients with severe 
symptoms is described in other articles of the Nordic Theme 
2016. 
Regarding TMJ surgery, numerous articles over the past 35 
years have dealt with interventions of the TMJ from injections 
to open surgery, but these interventions have not yet been suffi-
ciently evaluated except for ankylosis cases or severe functional 
disturbances (27). Controlled trials have been sparse and com-
parison of different treatment strategies is therefore important. 
Schiffman et al (28) found no difference between treatment 
strategies relative to any treatment outcome of medical treat-
ment; non-surgical rehabilitation, arthroscopic surgery and 
open TMJ surgery. Further studies are needed to evaluate the 
long-term effects of different treatment modalities. To compare 
the outcome of different treatments it is necessary to use stand-
ardized evaluation methods such as diagnostic criteria for TMD 
(28) or surgical classifications for TMD (29).
Persistent idiopathic facial pain and atypical odontalgia
Persistent idiopathic facial pain (PIFP), also known as atypical 
facial pain (AFP), is defined as a chronic facial pain in which 
signs of structural pathology or other specific causes of pain are 
not identified. The term atypical odontalgia (AO) is used when 
chronic pain is felt in a tooth region. AO is considered a sub-
category of PIFP (30). Prevalence and incidence estimates of 
PIFP and AO are limited, but both are rare conditions. Clinical 
case series indicate a preponderance of middle-aged or older 
women among PIFP patients, and chronicity of the symptoms.
PIFP is usually felt as deep, poorly localized continuous 
pain. Up to one third may experience bilateral pain. The pain 
is aching, throbbing, or pressing, and the intensity varies from 
moderate to severe. AO patients report persistent, moderately 
intense, usually well localized intraoral pain. The pain can 
include any tooth or mucosa of an extraction site, and it may 
move from tooth to tooth following dental procedures. Many 
PIFP and AO patients report that the onset of pain is related 
to some type of trauma or surgical procedure, e.g. endodontic 
treatment, extraction of teeth, or sinus surgery (31).
The diagnoses of PIFP and AO can only be made after care-
ful exclusion of pathology in teeth or adjacent structures, 
neurological disorders, and related systemic diseases, which 
may demand collaboration with several medical specialties. 
A thorough clinical and radiological examination is essential. 
Examination of trigeminal sensory function with neurophysi-
ologic recordings and quantitative sensory tests (QST) are rec-
ommended to improve diagnostic accuracy, as well as head MRI 
examination to exclude intracranial pathology. As always in 
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cases of chronic pain, attention should also be paid to possible 
psychological distress (31).
In recent years, clinical neurophysiology, QST, and func-
tional brain imaging have provided sensitive tools for detailed 
investigation of pain mechanisms (32). Clinical neurophysi-
ological studies have revealed nerve fibre dysfunction in PIFP 
and AO (33,34). Damage to the large tactile nerve fibres and 
the trigeminal brainstem complex may also occur in both con-
ditions. PET scanning of the brain dopamine system has sug-
gested that PIFP may be associated with striatal dopaminergic 
hypofunction (35). The current evidence supports the concept 
that in the majority of patients with PIFP and AO, the condition 
is a subclinical trigeminal neuropathic pain arising from minor 
peripheral nerve trauma or a more central trigeminal system 
lesion (31). 
There are no curative treatments available for PIFP and AO, 
and patients frequently have difficulties in accepting these di-
agnoses and their management, seeking help from different 
specialists, and therefore potentially receiving unnecessary in-
vasive dental and surgical treatments, which carry a high risk of 
pain aggravation. This stresses the need for patient education, 
and management should be multidisciplinary as the pain is of-
ten complicated by physical and psychiatric co-morbidity (31). 
Randomized controlled trials performed on PIFP and AO are 
scarce. However, the experience gained in treatment of other 
neuropathic pain conditions (36) can be transferred to PIFP and 
AO. The recommended pharmacologic treatment of PIFP and 
AO includes tricyclic antidepressants and gabapentinoids. Be-
havioural therapies are beneficial complements to biomedical 
approaches.
Trigeminal neuralgia
Trigeminal neuralgia (TN) is neuropathic pain with specific 
characteristics. The classical type of TN is a sudden, unilat-
eral, superficial, shooting or electric-shock like pain occurring 
repeatedly within the distribution of one or more branches of 
the trigeminal nerve (30). TN is most common in the maxillary 
and mandibular branch, and the paroxysms usually last some 
seconds, but may persist up to 2 minutes. The attacks are often 
initiated by non-painful physical stimulation of specific areas, 
trigger points. The frequency of the paroxysms varies from a 
few to even hundreds per day, but there may also be remission 
periods with days or even months without attacks. In addition 
to the classical paroxysmal pain attacks, TN patients may also 
suffer from continuous background pain, especially those with 
more chronic condition (30). 
TN is a rare; the presented incidence rates range from 12.6/ 
100 000 person years to 28.9/100,000 person years (37). The 
incidence increases with age, and is highest in patients older 
than 60 years.
The diagnosis of TN can only be made on clinical grounds, 
and is based on the patient’s pain description, and may there-
fore be mistaken for tooth pain, by patients, dentists and medi-
cal specialists. When the diagnosis of TN is suspected, the pa-
tient should be sent to neurologists for the confirmation of the 
diagnosis, and necessary further examinations. Brain MRI is 
considered a routine examination for TN patients. Very rarely, 
posterior fossa tumours may cause typical TN pain. In younger 
patients with TN symptoms, the possibility of multiple sclerosis 
should be considered, as TN may be the first manifestation of 
the disease. 
Dentists should know the characteristic features of TN, espe-
cially because it is important to differentiate the brief, intense, 
shooting type of pain in TN from pain of dental origin, because 
of the similarities between TN and dental conditions such as 
pulpitis and cracked tooth syndrome. As a result patients with 
TN may be treated with ineffective dental treatments. The pain 
provoking factors aid in differential diagnostics: TN is provoked 
by tactile stimuli such as touching the skin or brushing the 
teeth, whereas tooth pain is provoked by thermal (cold or hot) 
and sweet stimuli or percussion or pressure on the teeth.
The aetiology of TN is considered to be due to compression 
of the trigeminal nerve root by a vascular loop in the posterior 
fossa. This is thought to lead to local changes, such as disruption 
of myelin sheet, ephaptic conduction, and secondary hyperex-
citability, which can explain most of the characteristics of TN 
(38). 
The treatment of TN is usually pharmacological. Standard 
treatment is with anticonvulsants, and the first choice is usually 
carbamazepine, but the efficacy may be compromised by poor 
tolerability and pharmacokinetic interactions. A better-toler-
ated alternative is oxcarbazepine with similar efficacy. Other 
anticonvulsants may be used as add-on medications (39). Neu-
rosurgical procedures, preferably microvascular decompres-
sion surgery should be considered in case of poor response to 
pharmacotherapy or because of intolerable side effects caused 
by medication (40). 
Painful posttraumatic trigeminal neuropathy
Trigeminal neuropathic pain may arise from intra- or extra-
cranial lesions within the trigeminal system or general diseases 
Persistent facial pains, es-
pecially temporomandibular 
disorders are common condi-
tions in the adult population. 
Their symptoms may be quite 
similar to pain arising from the 
teeth and periodontium. It is 
therefore important for the 
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knowledge of the diagnosis 
and treatment of different 
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causing peripheral neuropathy such as diabetes, connective 
tissue diseases, or herpes zoster infection. The most important 
form of trigeminal neuropathic pain which dentists, and espe-
cially oral- and maxillofacial surgeons, should be aware of is, 
however, neuropathic pain caused by iatrogenic nerve damage. 
This entity belongs to peripheral painful posttraumatic trigemi-
nal neuropathies (PPTTN). These are defined by a history of an 
identifiable traumatic event to the trigeminal nerve with clini-
cally or neurophysiologically evident signs of sensory altera-
tion, and pain which is located within the affected trigeminal 
distribution and has developed within 3-6 months of the trau-
matic event (30).
Many dental and surgical procedures, such as orthognathic 
surgery, third molar extraction, implant surgery, root canal 
therapy, and even local anaesthesia carry a risk of trigeminal 
nerve damage. Fortunately, neuropathic pain evolves in only a 
minority of these. The incidence of PPTTN has been reported to 
vary from 3 % to 6 % after endodontic treatment, and to be 5 
% after surgical endodontics, 5 % after mandibular sagittal os-
teotomy, and 3 % after facial fractures. The prognosis of nerve 
damage greatly depends on the type of the damage; injuries in 
which only the myelin sheath is involved usually recover com-
pletely within four months, whereas the recovery of axonal 
injuries is much slower, and mostly incomplete. Posttraumatic 
neuropathic pain has been particularly related to axonal nerve 
damage of the small fibre system (41). Other risk factors for de-
velopment of neuropathic pain include genetic factors, comor-
bid pain or psychosocial distress (42,43).
PPTTN is described as moderate to severe pain, which usu-
ally occurs consistently or daily. The pain is often characterized 
as burning, lancinating, stubbing, pressing or tingling (44), and 
is accompanied by sensory alterations, in most cases in the form 
of reduced function. Diagnosis of PPTTN can in some cases be 
straightforward when a patient after a procedure reports senso-
ry symptoms and pain that persists beyond the normal healing 
time of tissue injury. However, after minor nerve injuries, sen-
sory signs may not be obvious in clinical examination. There-
fore thorough history taken with respect to previous surgery 
and trauma is important. Clinical sensory tests should be done 
carefully, testing different sensory modalities, but they are too 
crude to detect minor or old nerve injuries (41). Clinical neuro-
physiology offers many sensitive methods such as neurography, 
blink reflex test, QST and contact heat or laser evoked potential 
recordings to confirm the diagnosis, to localize the lesion, and 
to assess the type and profile of nerve fibre damage, which form 
the prerequisite for reliable appraisal of the prognosis (41). The 
tests are available in major hospitals of Nordic countries and 
they offer objective means to diagnose nerve damage, which is 
especially valuable in litigation cases.
The treatment of neuropathic pain relies mainly on pharma-
cotherapy, but thorough patient information, and helping pa-
tients to cope with the pain are essential parts of the treatment 
process, too. Surgical procedures are usually of no use, and 
can exacerbate the pain. First line drugs to treat neuropathic 
pain include tricyclic antidepressants, serotonin-noradrenaline 
reuptake inhibitors, gabapentin and pregabalin (36). Thera-
Pain 
character
Other symptoms,
findings
Location Duration Provoking/ag-
gravating factors
TMD Aching, pressing, 
stabbing 
Muscle/joint  
tenderness,
functional  
disturbances,
joint sounds 
Cheek, temple,  
TMJ region 
Varying, often con-
tinuous 
Jaw opening, 
chewing 
PIFP/AO Aching, pressing Usually none, subtle 
sensory symptoms 
possible
Varying/ tooth 
region
Continuous Psychological 
factors
TN Sharp, brief, electric 
shock like
Usually none Trigeminal nerve 
distribution
Seconds – a few 
minutes
Tactile stimuli
Neuropathic pain Burning, tingling, 
aching
Sensory alterations Trigeminal nerve 
distributions
Continuous, may 
fluctuate in intensity
Often: Tactile/ 
thermal stimuli
Facial pain conditions
Table 1. Frequent features of different facial pain conditions.
Tabel 1. Karakteristiske træk ved faciale smertetilstande.
TMD; temporomandibular disorder, TMJ; temporomandibular joint, PIFP; persistent idiopathic facial pain, AO; atypical odontalgia, TN; 
Trigeminal neuralgia
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peutic brain stimulation (transcranial magnetic stimulation 
and motor cortex stimulation) offers a novel treatment line for 
treatment-resistant neuropathic pain within the orofacial re-
gion (45). 
Differential diagnostics
Correct diagnosis is the sine qua non of successful treatment. 
Table 1, which features the most common or typical signs of 
different facial pain conditions, aims to provide a basis for the 
diagnostic work-up of chronic facial pain conditions. 
Concluding remarks and future scenarios
Considerable progress has been made during the last decades 
in the understanding of the processes involved in facial pain. 
The complexity and multidimensionality of pain is increasingly 
comprehended, and more insights have been gained into the 
risk factors predisposing to chronic pain. In addition, improved 
and more reliable diagnostic systems and approaches have 
been introduced, and some advances have been made in the 
treatment of certain facial pain entities, such as neuropathic fa-
cial pains. However, many aspects of facial pain are still poorly 
understood, and much needs to be done to validate many of 
the methods used to treat facial pain, and to develop new im-
proved, more effective treatment approaches with fewer side 
effects. 
Science is advancing rapidly in the field of pain, including 
facial pain. The special areas of interest in facial pain research 
include molecular biology, biomarkers, imaging, genetics, and 
pain and psychological comorbidities, among others. It is to be 
expected that increased understanding of the pain mechanisms 
and other aspects of facial pain will in the future bring some 
novel therapeutic possibilities. For our patients a correct treat-
ment is of uttermost importance. Treatment of chronic pain 
disorders have to be based on correct diagnosis and evidence 
based treatment modalities. The future will most probably also 
witness the rise of personalized pain medicine, where treat-
ments are customized to fit each patient’s pain and psychoso-
cial, as well as genetic characteristics. In the light of rapid ad-
vances in the field of pain, much more emphasis should be put 
on pain education in the dental curriculums.
ABSTRACT (DANSK)
Persisterende faciale smertetilstande
Kroniske ansigtssmerter er en almindeligt forekommende li-
delse, i særdeleshed i forbindelse med temporomandibulær 
dysfunktion (TMD). Da tandlæger er ansvarlige for behand-
lingen af de fleste af disse tilstande, er opdateret viden om 
de nyeste fremskridt inden for området helt afgørende for 
at kunne foretage vellykket diagnostik og behandling. Denne 
oversigt omfatter TMD og forskellige typer af neuropatiske 
eller formodede neuropatiske ansigtssmerter i form af ved-
varende idiopatiske ansigtssmerter og atypisk odontalgia, 
trigeminusneuralgi og smertefuld posttraumatisk trigeminus 
neuropati. Artiklen giver et overblik over TMD-smerter som en 
biopsykosocial tilstand, dens prævalens, karakteristika, cen-
trale og perifere mekanismer, diagnostik (DC/TMD) og prin-
cipper for behandling. Ligeledes beskrives definitioner, præ-
valens, karakteristika og diagnostik for hver af de forskellige 
typer af neuropatiske ansigtssmerter. Den aktuelle forståelse 
af patofysiologien af disse neuropatiske tilstande præsente-
res, og der gives en beskrivelse af de evidensbaserede be-
handlingsmetoder.
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